The Latest Breaking News from Eliem rapeutics

Eliem Concludes Patient Enrolment In Mid-Stage Study Of Radicular Back Pain Drug

Eliem Therapeutics (NASDAQ: ELYM) has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP).

Benzinga · Jun 27, 2022

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Benzinga · Jun 13, 2022

12 Health Care Stocks Moving In Wednesday's Intraday Session

 

Benzinga · Jun 1, 2022